Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 10/20 | 0.80 |
| ▸ | DOT1L | Q8TEK3 | 5/20 | 0.80 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | GALR3 | O60755 | 1/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.65 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.65 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toyocamycin SCHEMBL2786616 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL17395285 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL29363964 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL13064386 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL20438004 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL14642992 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL14642728 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL6674952 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| Toyocamycin SCHEMBL2786620 | 1.00 | ADK (0.80) | ADKDOT1LPAX8NPC1GALR3 | |
| SCHEMBL16978197 | 0.89 | ADK (1.00) | ADKDOT1LPAX8NPC1GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 877 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | claimed |
| WO-2025093883-A1 | DRESSING | THE UNIVERSITY OF BATH (GB) | 2025-05-08 | — | — | WO | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20250082663-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE (ADPLD) AND/OR AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | UNIV YALE (US) | 2025-03-13 | — | — | US | claimed |
| CN-118995552-A | Streptomyces albus mutant strain, construction method and application | 贵州省烟草科学研究院 | 2024-11-22 | — | — | CN | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| EP-4355356-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE (ADPLD) AND/OR AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Yale University (US) | 2024-04-24 | — | — | EP | claimed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| US-20030060457-A1 | Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2003-03-27 | — | — | US | claimed |
| WO-2002072891-A1 | FLUORESCENCE ASSAY FOR DNA MODIFYING ENZYMES | UNIVERSITY OF CALIFORNIA (US) | 2002-09-19 | — | — | WO | claimed |
| US-20020127593-A1 | Fluorescence assay for DNA modifying enzymes | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-12 | — | — | US | claimed |
| WO-2002053096-A2 | SINGLE THERAPY AND COMBINATION THERAPY INVOLVING DRUGS WITH TARGET CELLULAR PROTEINS AND DRUGS WHICH TARGET PATHOGEN-ENCODED PROTEINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-07-11 | — | — | WO | claimed |
| WO-2002030410-A2 | SUPPRESSION OF CYCLIN KINASE ACTIVITY FOR PREVENTION AND TREATMENT OF INFECTIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-04-18 | — | — | WO | claimed |
| US-5872104-A | BACTERICIDES AND RESISTANT BACTERIA WITH METHYLATION INHIBITORS | ORIDIGM CORPORATION (US) | 1999-02-16 | — | — | US | claimed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | claimed |
| WO-1992005200-A1 | XENOBIOTIC-ANTIBODY CONJUGATES | CHEMEX PHARMACEUTICALS, INC. (US) | 1992-04-02 | — | — | WO | claimed |
| US-4389483-A | AEROBIC CULTURING A MUTANT OF BREVIBACTERIUM OR COPYNEBACTERIUM | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-06-21 | — | — | US | claimed |
| US-4088756-A | TREATING PSORIASIS, DERMATITIS WITH ADRENERGIC AGENTS AND HYPOGLYCEMIC AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1978-05-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | MIF, CCL2, MPEG1 | ADK 3165/4885DOT1L 2062/4885PAX8 2565/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | ADK 3678/4885DOT1L 2574/4885PAX8 2094/4885 |
| US-20250082663-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE (ADPLD) AND/OR AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | PKD1, PKD2, FAHD1 | ADK 107/4885DOT1L 1939/4885PAX8 962/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | ADK 2745/4885DOT1L 3382/4885PAX8 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.